Literature DB >> 9018462

Systemic and localized scleroderma in children.

T J Lehman1.   

Abstract

All forms of scleroderma are rare in childhood. The most common form in childhood is localized scleroderma, which may take the form of morphea or linear scleroderma. Localized scleroderma is often benign but may cause significant deformity if it occurs on the face or extends across joint surfaces. Progressive systemic sclerosis is much less frequent in childhood but may have a rapidly progressive and ultimately fatal course. CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangieactasia) syndrome also may occur in childhood with manifestations similar to those seen in adults. In addition, some children in whom mixed connective tissue disease is initially diagnosed ultimately develop progressive systemic sclerosis. Research into both the causes and the optimal therapy for childhood scleroderma is hampered by the small number of patients treated at individual centers. This limitation has made it difficult to perform well-controlled studies.

Entities:  

Mesh:

Year:  1996        PMID: 9018462     DOI: 10.1097/00002281-199611000-00013

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  4 in total

Review 1.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Clinical trials for pediatric scleroderma.

Authors:  Margalit E Rosenkranz; Thomas J A Lehman
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 3.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Progressive systemic sclerosis in a child.

Authors:  Arun K De; Kallol Das; Archan Sil; Swarnali Joardar
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.